UF startup Algernon Pharmaceuticals Inc., formerly known as Breathtec Biomedical, announced that it has signed an agreement with Charles River Laboratories for preclinical studies of AP-188 (N,N-Dimethyltryptamine or DMT) for the company’s stroke clinical research program.
Included in this news roundup is UF startup Algernon Pharmaceuticals's trials with ifenprodil, a drug used to treat vertigo and bird flu. Algernon is testing the drug's efficacy in preventing lung damage and increasing survivability in patients with COVID-19.
UF startup Algernon Pharmaceuticals Inc., formerly known as Breathtec Biomedical, a clinical-stage pharmaceutical development company, announced that the external Data and Safety Monitoring Board (“DSMB”) has completed its latest review of the Phase 2b part of the Company’s Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, and has provided approval for the company to continue on with the Phase 3 part of the study.
Christopher Moreau, CEO of UF startup Algernon Pharmaceuticals, a clinical-stage pharmaceutical development company, joined Steve Darling from Proactive Vancouver to discuss another development... Read More